<!DOCTYPE html>
<html lang="en">
<head>
  <!-- Google tag (gtag.js) -->
  <script async src="https://www.googletagmanager.com/gtag/js?id=G-LSRR4KW715"></script>
  <script>
    window.dataLayer = window.dataLayer || [];
    function gtag(){dataLayer.push(arguments);
    }
    gtag('js', new Date());

    gtag('config', 'G-LSRR4KW715');
  </script>


  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Case 29.7 - Genital Herpes [SDL]</title>

  <!-- Favicon -->
  <link rel="icon" type="image/png" href="../assets/ShepTech logo.png">
  <link rel="apple-touch-icon" href="../assets/ShepTech logo.png">

  <!-- Primary Meta Tags -->
  <meta name="title" content="Case 29.7 - Genital Herpes [SDL] | MD3 SCP Cases">
  <meta name="description" content="Self-directed learning case on genital herpes (HSV-1 and HSV-2) covering primary infection, recurrence, diagnosis, antiviral treatment, and pregnancy management.">

  <!-- Open Graph / Facebook -->
  <meta property="fb:app_id" content="your_facebook_app_id">
  <meta property="og:type" content="article">
  <meta property="og:url" content="https://md3-scp.netlify.app/cases/case29_7.html">
  <meta property="og:title" content="Case 29.7 - Genital Herpes [SDL]">
  <meta property="og:site_name" content="MD3 SCP Cases">
  <meta property="og:description" content="Self-directed learning case on genital herpes (HSV-1 and HSV-2) covering primary infection, recurrence, diagnosis, antiviral treatment, and pregnancy management.">
  <meta property="og:image" content="https://md3-scp.netlify.app/assets/ShepTech%20logo.png">
  <!-- Twitter -->
  <meta property="twitter:card" content="summary">
  <meta property="twitter:title" content="Case 29.7 - Genital Herpes [SDL]">
  <meta property="twitter:description" content="Self-directed learning case on genital herpes (HSV-1 and HSV-2) covering primary infection, recurrence, diagnosis, antiviral treatment, and pregnancy management.">
  <meta property="twitter:image" content="https://md3-scp.netlify.app/assets/ShepTech%20logo.png">

  <link rel="stylesheet" href="../css/case.css">

  <!-- Firebase SDK -->
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-app-compat.js"></script>
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-auth-compat.js"></script>
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-firestore-compat.js"></script>
</head>
<body>
  <div class="container">
    <div class="case-header">
      <a href="#" class="back-link" onclick="goBack(event)">← Back to Cases</a>
    </div>

    <h1>Case 29.7 – Genital Herpes [SDL]</h1>
    <p class="meta"><strong>Category:</strong> Medicine | <strong>Discipline:</strong> Sexual Health | <strong>Setting:</strong> Self-Directed Learning</p>

    <h2>Learning Objectives</h2>
    <p>This is a <strong>self-directed learning (SDL)</strong> case. Use the key learning points below to guide your independent study of genital herpes.</p>

    <h2>Key Topics to Cover</h2>
    <div class="key-points">
      <ul>
        <li><strong>Definition:</strong> Genital herpes = sexually transmitted infection caused by <strong>herpes simplex virus (HSV)</strong> - chronic, lifelong infection with latency and recurrence</li>
        <li><strong>Causative organisms:</strong>
          <ul>
            <li><strong>HSV-2:</strong> Traditional "genital herpes" - 70% of genital herpes cases, more frequent recurrences</li>
            <li><strong>HSV-1:</strong> Traditional "oral herpes" (cold sores) - now accounts for 30% of genital herpes (due to oral sex), fewer recurrences</li>
            <li><strong>Cannot distinguish HSV-1 from HSV-2 clinically</strong> - requires lab testing</li>
          </ul>
        </li>
        <li><strong>Epidemiology:</strong> Very common - 1 in 5 adults in UK seropositive for HSV-2 (most asymptomatic), incidence increasing (especially HSV-1 genital infections)</li>
        <li><strong>Transmission:</strong>
          <ul>
            <li>Sexual contact (genital-genital, oral-genital) - transmitted via skin-to-skin contact with infected lesions or asymptomatic viral shedding</li>
            <li><strong>Asymptomatic shedding</strong> (virus present on genital skin without lesions) - accounts for 70% of transmission</li>
            <li>Vertical transmission (mother-to-neonate) - risk highest with primary infection in late pregnancy (30-50% transmission risk)</li>
          </ul>
        </li>
        <li><strong>Clinical features:</strong>
          <ul>
            <li><strong>Primary infection (first episode - MOST SEVERE):</strong>
              <ul>
                <li><strong>Incubation:</strong> 2-12 days (average 4 days)</li>
                <li><strong>Symptoms:</strong> Multiple painful genital ulcers (vesicles → ulcers → crusts), severe pain, dysuria, inguinal lymphadenopathy, systemic symptoms (fever, malaise, myalgia)</li>
                <li><strong>Duration:</strong> 2-3 weeks (lesions heal without scarring)</li>
                <li><strong>Complications:</strong> Urinary retention (severe dysuria), aseptic meningitis (10-30% of primary infections), sacral radiculopathy</li>
              </ul>
            </li>
            <li><strong>Recurrent infection (MILDER):</strong>
              <ul>
                <li><strong>Trigger:</strong> Virus reactivates from dorsal root ganglia (latency) - triggered by stress, illness, UV exposure, immunosuppression</li>
                <li><strong>Symptoms:</strong> Fewer lesions (usually &lt;5), less pain, no systemic symptoms</li>
                <li><strong>Duration:</strong> 7-10 days (shorter than primary)</li>
                <li><strong>Frequency:</strong> Variable - HSV-2 (median 4 recurrences/year, decreases over time), HSV-1 (fewer recurrences - median 1/year)</li>
                <li><strong>Prodrome:</strong> Tingling, itching, burning sensation 12-24 hours before lesions appear</li>
              </ul>
            </li>
            <li><strong>Atypical presentations:</strong> Fissures, erythema, atypical ulcers (especially in immunosuppressed - larger, deeper, longer-lasting)</li>
          </ul>
        </li>
        <li><strong>Diagnosis (BASHH 2014 Guidelines):</strong>
          <ul>
            <li><strong>NAAT/PCR on lesion swab (GOLD STANDARD):</strong> Detects HSV DNA, type-specific (distinguishes HSV-1 vs HSV-2) - highest sensitivity</li>
            <li><strong>Viral culture:</strong> Less sensitive than PCR (especially in recurrent infection or healing lesions) - no longer recommended as first-line</li>
            <li><strong>HSV serology (IgG):</strong> Detects past infection (seroprevalence) - <strong>NOT useful for acute diagnosis</strong> (takes 12 weeks to seroconvert), limited clinical utility (cannot distinguish genital vs oral site, high background seroprevalence)</li>
            <li><strong>Swab technique:</strong> Unroof vesicle, swab base of ulcer vigorously - send in viral transport medium</li>
          </ul>
        </li>
        <li><strong>Management (BASHH 2014 Guidelines):</strong>
          <ul>
            <li><strong>Primary infection - Antiviral treatment (start immediately, ideally within 5 days of symptom onset):</strong>
              <ul>
                <li><strong>Aciclovir 400mg TDS for 5 days</strong> (or valaciclovir 500mg BD for 5 days)</li>
                <li><strong>Effect:</strong> Reduces symptom duration, viral shedding, complications (does NOT cure infection or prevent recurrences)</li>
                <li><strong>Analgesia:</strong> Paracetamol, ibuprofen, topical lidocaine gel</li>
                <li><strong>Advise:</strong> Saline bathing, avoid sex until lesions healed, plenty of fluids (prevent urinary retention)</li>
              </ul>
            </li>
            <li><strong>Recurrent infection:</strong>
              <ul>
                <li><strong>Episodic treatment:</strong> Aciclovir 800mg TDS for 5 days (or valaciclovir 500mg BD for 3-5 days) - <strong>start at first sign of prodrome</strong> (most effective if started early)</li>
                <li><strong>Suppressive therapy (if ≥6 recurrences/year or severe psychological impact):</strong>
                  <ul>
                    <li>Aciclovir 400mg BD (or valaciclovir 500mg OD) - continuous daily dosing</li>
                    <li><strong>Effect:</strong> Reduces recurrence frequency by 70-80%, reduces asymptomatic shedding (lowers transmission risk), improves quality of life</li>
                    <li><strong>Duration:</strong> Review after 12 months (consider stopping to reassess recurrence frequency)</li>
                  </ul>
                </li>
              </ul>
            </li>
            <li><strong>Partner management:</strong>
              <ul>
                <li>Offer partner screening (often asymptomatic)</li>
                <li><strong>Counsel on transmission risk:</strong> Asymptomatic shedding occurs, condoms reduce risk (50%), suppressive therapy reduces transmission risk (48%)</li>
                <li>Avoid sex during outbreaks (highest transmission risk)</li>
              </ul>
            </li>
          </ul>
        </li>
        <li><strong>Pregnancy and neonatal herpes:</strong>
          <ul>
            <li><strong>Neonatal herpes:</strong> Rare (1.65 per 100,000 live births in UK) but severe - mortality 30% (untreated), neurological sequelae 50%</li>
            <li><strong>Risk of transmission:</strong>
              <ul>
                <li><strong>Primary infection in 3rd trimester (especially at delivery):</strong> 30-50% transmission risk (NO maternal antibodies to protect neonate)</li>
                <li><strong>Recurrent infection at delivery:</strong> \&lt;3% transmission risk (maternal antibodies protective)</li>
                <li><strong>Established infection before pregnancy:</strong> Very low risk (\&lt;1%)</li>
              </ul>
            </li>
            <li><strong>Management (RCOG 2014 Guidelines):</strong>
              <ul>
                <li><strong>Primary infection in 1st/2nd trimester:</strong> Aciclovir 400mg TDS (safe in pregnancy), vaginal delivery likely safe</li>
                <li><strong>Primary infection in 3rd trimester (≥28 weeks):</strong>
                  <ul>
                    <li>Aciclovir 400mg TDS until delivery</li>
                    <li><strong>Offer elective caesarean section at 39 weeks</strong> (if primary infection within 6 weeks of delivery) - reduces neonatal herpes risk</li>
                  </ul>
                </li>
                <li><strong>Recurrent infection:</strong> Vaginal delivery safe (low transmission risk), offer suppressive aciclovir from 36 weeks (reduces recurrence at delivery)</li>
                <li><strong>Lesions at onset of labour:</strong> Offer caesarean section (reduces neonatal exposure)</li>
              </ul>
            </li>
          </ul>
        </li>
        <li><strong>Key counselling points:</strong>
          <ul>
            <li><strong>Genital herpes is a chronic, lifelong infection</strong> (no cure) - virus remains latent in dorsal root ganglia</li>
            <li><strong>Recurrences are common but usually milder</strong> (frequency decreases over time)</li>
            <li><strong>Transmission can occur without visible lesions</strong> (asymptomatic shedding) - condoms reduce risk but do not eliminate it</li>
            <li><strong>Psychological impact:</strong> Stigma, anxiety, depression - offer counselling, support groups (Herpes Viruses Association)</li>
            <li><strong>Most people with HSV are asymptomatic</strong> (unaware they have infection) - normalizing diagnosis important</li>
          </ul>
        </li>
      </ul>
    </div>

    <h2>Recommended Resources</h2>
    <p>Refer to your lecture notes, textbooks (e.g., Oxford Handbook of Genitourinary Medicine, BASHH guidelines 2014), and online resources (BASHH, Herpes Viruses Association, RCOG Green-top Guideline No. 30) to explore these topics in detail.</p>

  </div>

  <!-- JavaScript -->  <script src="../js/firebase-config.js"></script>
  <script src="../js/dark-mode.js"></script>
  <script src="../js/auth.js"></script>
  <script src="../js/user-analytics.js"></script>
  <script src="../js/analytics-integration.js"></script>
  <script src="../js/completion-tracker.js"></script>
  <script src="../js/flag-tracker.js"></script>
  <script src="../js/case-interactions.js"></script>

  <script>
    // Toggle case completion
    function toggleCaseCompletion() {
      if (window.completionTracker) {
        const caseId = window.completionTracker.getCurrentCaseId();
        if (caseId) {
          window.completionTracker.toggleCompletion(caseId);
        
    }
      
    }
    
    }
// Toggle case flag
    function toggleCaseFlag() {
      console.log('toggleCaseFlag() function called');
      console.log('window.flagTracker exists:', !!window.flagTracker);

      if (!window.flagTracker) {
        console.error('window.flagTracker is not defined!');
        alert('Flag tracker not initialized. Please refresh the page.');
        return;
      
    }

      const caseId = window.flagTracker.getCurrentCaseId();
      console.log('Current case ID:', caseId);

      if (!caseId) {
        console.error('Could not get case ID');
        alert('Could not determine case ID');
        return;
      
    }

      console.log('Calling window.flagTracker.toggleCaseFlag with caseId:', caseId);
      window.flagTracker.toggleCaseFlag(caseId);
    
    }

    // Update case flag button state on page load
    document.addEventListener('DOMContentLoaded', () => {
      if (window.flagTracker) {
        setTimeout(() => {
          const caseId = window.flagTracker.getCurrentCaseId();
          if (caseId) {
            window.flagTracker.updateCaseFlagButton(caseId);
          
    }
        }, 100);
      
    }
    });
    
    }
  </script>

</body>
</html>
